List of Recarbrio drug patents

Recarbrio is owned by Msd Merck Co.

Recarbrio contains Cilastatin Sodium; Imipenem; Relebactam.

Recarbrio has a total of 1 drug patent out of which 0 drug patents have expired.

Recarbrio was authorised for market use on 16 July, 2019.

Recarbrio is available in powder;intravenous dosage forms.

Recarbrio can be used as treatment of complicated intra-abdominal infections (ciai); treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); treatment of complicated urinary tract infections, including pyelonephritis (cuti).

Drug patent challenges can be filed against Recarbrio from 2028-07-16.

The generics of Recarbrio are possible to be released after 19 November, 2029.

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 2028-07-16

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

4

United States

3

Lithuania

3

Japan

2

Denmark

2

Hong Kong

2

Slovenia

2

Hungary

2

Croatia

2

Portugal

2

Cyprus

2

Spain

2

Netherlands

2

Korea, Republic of

2

Poland

2

RS

2

China

2

Ecuador

2

European Union

1

Israel

1

South Africa

1

Mexico

1

Australia

1

Russia

1

Morocco

1

Norway

1

Costa Rica

1

Colombia

1

Honduras

1

Brazil

1

Malaysia

1

Dominican Republic

1

Luxembourg

1

Nicaragua

1

Ukraine

1

Canada

1

New Zealand

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in